IGF1 and acromegaly: Of those patients in the CAM2029 arm who were classified as nonresponders for the primary endpoint, all had IGF-1 values <1.3 × ULN (threshold for diagnosis of acromegaly) at the end of the trial, except for 1 patient with a single high IGF-1 value at week 22 (which subsequently decreased to <ULN at week 24).